Pancreatic cancer and liver metastases: state of the art

摘要: Pancreatic cancer is still one of the most aggressive oncological diseases with a 5-year mortality rate below 10%. Surgery remains only curative treatment; however, patients present late-stage disease deemed unresectable, either due to extensive local vascular involvement or presence distant metastasis. In detection hepatic metastases, current standard palliative chemotherapy fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) nab-paclitaxel gemcitabine. Once metastases are diagnosed, guidelines do not recommend resection primary tumor. Recent findings suggest that some non-resectable initially have survival rates as good those resectable when they able undergo surgical resection. Synchronous both tumour well liver may be beneficial improves outcome.